Premium
Developing novel blood‐based biomarkers for Alzheimer's disease
Author(s) -
Snyder Heather M.,
Carrillo Maria C.,
Grodstein Francine,
Henriksen Kim,
Jeromin Andreas,
Lovestone Simon,
Mielke Michelle M.,
O'Bryant Sid,
Sarasa Manual,
Sj⊘gren Magnus,
Soares Holly,
Teeling Jessica,
Trushina Eugenia,
Ward Malcolm,
West Tim,
Bain Lisa J.,
Shineman Diana W.,
Weiner Michael,
Fillit Howard M.
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2013.10.007
Subject(s) - disease , biomarker , drug development , medicine , alzheimer's disease , biomarker discovery , drug , psychiatry , pathology , biology , proteomics , biochemistry , gene
Alzheimer's disease is the public health crisis of the 21st century. There is a clear need for a widely available, inexpensive and reliable method to diagnosis Alzheimer's disease in the earliest stages, track disease progression, and accelerate clinical development of new therapeutics. One avenue of research being explored is blood based biomarkers. In April 2012, the Alzheimer's Association and the Alzheimer's Drug Discovery Foundation convened top scientists from around the world to discuss the state of blood based biomarker development. This manuscript summarizes the meeting and the resultant discussion, including potential next steps to move this area of research forward.